NO20030714D0 - Blandinger og fremgangsmåter for behandling og diagnose av HER-2/NEU-assosierte maligniteter - Google Patents
Blandinger og fremgangsmåter for behandling og diagnose av HER-2/NEU-assosierte maligniteterInfo
- Publication number
- NO20030714D0 NO20030714D0 NO20030714A NO20030714A NO20030714D0 NO 20030714 D0 NO20030714 D0 NO 20030714D0 NO 20030714 A NO20030714 A NO 20030714A NO 20030714 A NO20030714 A NO 20030714A NO 20030714 D0 NO20030714 D0 NO 20030714D0
- Authority
- NO
- Norway
- Prior art keywords
- neu
- diagnosis
- mixtures
- treatment
- methods
- Prior art date
Links
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 title 1
- 238000003745 diagnosis Methods 0.000 title 1
- 230000036210 malignancy Effects 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464403—Receptors for growth factors
- A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22515200P | 2000-08-14 | 2000-08-14 | |
US23642800P | 2000-09-28 | 2000-09-28 | |
US27052001P | 2001-02-21 | 2001-02-21 | |
PCT/US2001/041733 WO2002014503A2 (en) | 2000-08-14 | 2001-08-14 | Compositions and methods for the therapy and diagnosis of her-2/neu-associated malignancies |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20030714D0 true NO20030714D0 (no) | 2003-02-14 |
NO20030714L NO20030714L (no) | 2003-04-11 |
Family
ID=27397445
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20030714A NO20030714L (no) | 2000-08-14 | 2003-02-14 | Blandinger og fremgangsmåter for behandling og diagnose av HER-2/NEU-assosierte maligniteter |
Country Status (14)
Country | Link |
---|---|
US (1) | US20020193329A1 (no) |
EP (1) | EP1366153A2 (no) |
JP (1) | JP2004522412A (no) |
KR (1) | KR20030048009A (no) |
CN (1) | CN1537164A (no) |
AU (1) | AU2001295008A1 (no) |
BR (1) | BR0113235A (no) |
CA (1) | CA2419533A1 (no) |
HU (1) | HUP0600780A2 (no) |
IL (1) | IL154415A0 (no) |
MX (1) | MXPA03001389A (no) |
NO (1) | NO20030714L (no) |
PL (1) | PL365789A1 (no) |
WO (1) | WO2002014503A2 (no) |
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU6620300A (en) | 1999-08-03 | 2001-02-19 | Ohio State University, The | Polypeptides and polynucleotides for enhancing immune reactivity to her-2 protein |
TWI259206B (en) * | 2002-09-24 | 2006-08-01 | Univ Nat Cheng Kung | A DNA vaccine containing a tumor associated gene and a cytokine gene and the method producing thereof |
JP2006525787A (ja) | 2003-01-03 | 2006-11-16 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | アカゲザルHER2/neu、これをコードするヌクレオチド及びその使用 |
JP4772674B2 (ja) * | 2003-07-21 | 2011-09-14 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | ヒト上皮成長因子2/neu抗原をコードする合成遺伝子およびその用途 |
SG195524A1 (en) | 2003-11-06 | 2013-12-30 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugation to ligands |
KR20120064120A (ko) | 2004-06-01 | 2012-06-18 | 제넨테크, 인크. | 항체 약물 접합체 및 방법 |
US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
SI1791565T1 (sl) | 2004-09-23 | 2016-08-31 | Genentech, Inc. | Cisteinsko konstruirana protitelesa in konjugati |
CN100381460C (zh) * | 2004-11-30 | 2008-04-16 | 北京市肿瘤防治研究所 | Her-2模拟抗原表位及含有该表位的肽 |
US7691396B2 (en) * | 2005-06-15 | 2010-04-06 | The Ohio State University Research Foundation | Chimeric peptides comprising HER-2 B-cell epitopes and measles virus fusion protein T-cell epitopes |
KR101010063B1 (ko) * | 2008-07-25 | 2011-01-21 | 삼표이앤씨 주식회사 | 레일고정구조 |
US20100234283A1 (en) | 2009-02-04 | 2010-09-16 | The Ohio State University Research Foundation | Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use |
AU2010292172A1 (en) | 2009-09-09 | 2012-05-03 | Centrose, Llc | Extracellular targeted drug conjugates |
JP5972864B2 (ja) | 2010-04-15 | 2016-08-17 | メディミューン リミテッド | ピロロベンゾジアゼピン及びそれらのコンジュゲート |
AU2011265054B2 (en) | 2010-06-08 | 2016-09-15 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
CA2816426A1 (en) | 2010-11-17 | 2012-06-07 | Genentech, Inc. | Alaninyl maytansinol antibody conjugates |
KR101992502B1 (ko) | 2011-05-12 | 2019-06-24 | 제넨테크, 인크. | 프레임워크 시그너처 펩티드를 사용하여 동물 샘플에서 치료 항체를 검출하기 위한 다중 반응 모니터링 lc-ms/ms 방법 |
EP2750713B1 (en) | 2011-10-14 | 2015-09-16 | Spirogen Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
CN102357246B (zh) * | 2011-11-02 | 2013-04-03 | 江苏省中医药研究院 | 一种egfr与her2联合多肽表位疫苗 |
WO2013130093A1 (en) | 2012-03-02 | 2013-09-06 | Genentech, Inc. | Biomarkers for treatment with anti-tubulin chemotherapeutic compounds |
SI2906296T1 (en) | 2012-10-12 | 2018-06-29 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
BR112015008173A2 (pt) | 2012-10-12 | 2017-11-28 | Adc Therapeutics Sarl | conjugados de pirrolobenzodiazepina-anticorpo anti-psma |
JP6392763B2 (ja) | 2012-10-12 | 2018-09-19 | エイディーシー・セラピューティクス・エス・アーAdc Therapeutics Sa | ピロロベンゾジアゼピン−抗体結合体 |
SI2839860T1 (sl) | 2012-10-12 | 2019-07-31 | MedImmune Limited, | Pirolobenzodiazepini in njihovi konjugati |
US9919056B2 (en) | 2012-10-12 | 2018-03-20 | Adc Therapeutics S.A. | Pyrrolobenzodiazepine-anti-CD22 antibody conjugates |
EP2906297B1 (en) | 2012-10-12 | 2017-12-06 | ADC Therapeutics SA | Pyrrolobenzodiazepine-antibody conjugates |
EP2906250B1 (en) | 2012-10-12 | 2018-05-30 | ADC Therapeutics SA | Pyrrolobenzodiazepine-anti-psma antibody conjugates |
AU2013366490B9 (en) | 2012-12-21 | 2018-02-01 | Medimmune Limited | Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases |
EP2935268B2 (en) | 2012-12-21 | 2021-02-17 | MedImmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
AU2014230735B2 (en) | 2013-03-13 | 2018-03-15 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
MX364330B (es) | 2013-03-13 | 2019-04-23 | Medimmune Ltd | Pirrolobenzodiazepinas y conjugados de las mismas. |
SG11201507214SA (en) | 2013-03-13 | 2015-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
AU2014307080B2 (en) | 2013-08-12 | 2018-06-07 | Genentech, Inc. | 1-(chloromethyl)-2,3-dihydro-1H-benzo(E)indole dimer antibody-drug conjugate compounds, and methods of use and treatment |
WO2015052535A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
WO2015052532A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
US9950078B2 (en) | 2013-10-11 | 2018-04-24 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
MX371092B (es) | 2013-12-16 | 2020-01-16 | Genentech Inc | Compuestos peptidomimeticos y conjugados de anticuerpo-farmaco de los mismos. |
CN107106700B (zh) | 2013-12-16 | 2020-10-30 | 基因泰克公司 | 肽模拟化合物及其抗体-药物缀合物 |
JP6980384B2 (ja) | 2013-12-16 | 2021-12-15 | ジェネンテック, インコーポレイテッド | 1−(クロロメチル)−2,3−ジヒドロ−1h−ベンゾ[e]インドール二量体抗体−薬物コンジュゲート化合物、並びに使用及び処置の方法 |
EP3193940A1 (en) | 2014-09-10 | 2017-07-26 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
EP3191134B1 (en) | 2014-09-12 | 2019-11-20 | Genentech, Inc. | Anthracycline disulfide intermediates, antibody-drug conjugates and methods |
GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
CA2957354A1 (en) | 2014-09-12 | 2016-03-17 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
CA2959689A1 (en) | 2014-09-17 | 2016-03-24 | Genentech, Inc. | Pyrrolobenzodiazepines and antibody disulfide conjugates thereof |
CN107148285B (zh) | 2014-11-25 | 2022-01-04 | Adc治疗股份有限公司 | 吡咯并苯并二氮杂䓬-抗体缀合物 |
AU2015358532C1 (en) | 2014-12-03 | 2020-10-29 | Genentech, Inc. | Quaternary amine compounds and antibody-drug conjugates thereof |
GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
GB201506402D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
MA43345A (fr) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation |
MA43354A (fr) | 2015-10-16 | 2018-08-22 | Genentech Inc | Conjugués médicamenteux à pont disulfure encombré |
MA45326A (fr) | 2015-10-20 | 2018-08-29 | Genentech Inc | Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation |
GB201601431D0 (en) | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
GB201602359D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
GB201602356D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
EP4273551A3 (en) | 2016-03-25 | 2024-01-17 | F. Hoffmann-La Roche AG | Multiplexed total antibody and antibody-conjugated drug quantification assay |
GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
WO2017201449A1 (en) | 2016-05-20 | 2017-11-23 | Genentech, Inc. | Protac antibody conjugates and methods of use |
US20170370906A1 (en) | 2016-05-27 | 2017-12-28 | Genentech, Inc. | Bioanalytical analysis of site-specific antibody drug conjugates |
CN109476648B (zh) | 2016-06-06 | 2022-09-13 | 豪夫迈·罗氏有限公司 | 司维司群抗体-药物缀合物和使用方法 |
CN109689111B (zh) | 2016-08-11 | 2024-04-05 | 基因泰克公司 | 吡咯并苯并二氮杂䓬前药及其抗体缀合物 |
CN110139674B (zh) | 2016-10-05 | 2023-05-16 | 豪夫迈·罗氏有限公司 | 制备抗体药物缀合物的方法 |
GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
UA125198C2 (uk) | 2017-02-08 | 2022-01-26 | Ейдісі Терапьютікс Са | Кон'югати піролобензодіазепін-антитіло |
GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
SI3612537T1 (sl) | 2017-04-18 | 2022-10-28 | Medimmune Limited | Konjugati pirolobenzodiazepina |
CN110536703A (zh) | 2017-04-20 | 2019-12-03 | Adc治疗有限公司 | 使用抗axl抗体-药物缀合物的组合疗法 |
BR112019026564A2 (pt) | 2017-06-14 | 2020-06-30 | Adc Therapeutics Sa | regimes de dosagem para a administração de um adc anti-cd19 |
CN111065638B (zh) | 2017-08-18 | 2021-04-09 | 麦迪穆有限责任公司 | 吡咯并苯并二氮杂䓬缀合物 |
RU2020113749A (ru) | 2017-09-20 | 2021-10-20 | пиЭйч ФАРМА Ко., ЛТД. | Аналоги таиланстатина |
GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
GB201814281D0 (en) | 2018-09-03 | 2018-10-17 | Femtogenix Ltd | Cytotoxic agents |
CA3111381A1 (en) * | 2018-09-05 | 2020-04-30 | The Regents Of The University Of California | Composition of ny-eso-1-specific t cell receptors restricted on multiple major histocompatibility complex molecules |
EP3870235A1 (en) | 2018-10-24 | 2021-09-01 | F. Hoffmann-La Roche AG | Conjugated chemical inducers of degradation and methods of use |
CN113227119A (zh) | 2018-12-10 | 2021-08-06 | 基因泰克公司 | 用于与含Fc的蛋白质进行位点特异性缀合的光交联肽 |
GB201901197D0 (en) | 2019-01-29 | 2019-03-20 | Femtogenix Ltd | G-A Crosslinking cytotoxic agents |
GB2597532A (en) | 2020-07-28 | 2022-02-02 | Femtogenix Ltd | Cytotoxic compounds |
KR20240006547A (ko) | 2021-05-04 | 2024-01-15 | 주식회사 애스톤사이언스 | Her2 백신 조성물 |
KR20230017640A (ko) | 2021-07-28 | 2023-02-06 | 주식회사 애스톤사이언스 | Her2 백신 조성물 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993014781A1 (en) * | 1992-01-24 | 1993-08-05 | The Regents Of The University Of California | Novel peptides and method for altering the activity of allosteric proteins |
US5801005A (en) * | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
US5869445A (en) * | 1993-03-17 | 1999-02-09 | University Of Washington | Methods for eliciting or enhancing reactivity to HER-2/neu protein |
EP1064022A4 (en) * | 1998-03-13 | 2004-09-29 | Epimmune Inc | HLA BINDING PEPTIDES AND THEIR APPLICATIONS |
JP2002514573A (ja) * | 1998-05-08 | 2002-05-21 | スローン − ケッタリング インスティチュート フォー キャンサー リサーチ | 能動的なワクチン接種のための組成物および方法 |
NZ513062A (en) * | 1999-01-29 | 2003-10-31 | Smithkline Beecham | HER-2/neu fusion proteins |
-
2001
- 2001-08-14 KR KR10-2003-7002207A patent/KR20030048009A/ko not_active Application Discontinuation
- 2001-08-14 CN CNA018164471A patent/CN1537164A/zh active Pending
- 2001-08-14 CA CA002419533A patent/CA2419533A1/en not_active Abandoned
- 2001-08-14 US US09/930,125 patent/US20020193329A1/en not_active Abandoned
- 2001-08-14 AU AU2001295008A patent/AU2001295008A1/en not_active Abandoned
- 2001-08-14 HU HU0600780A patent/HUP0600780A2/hu unknown
- 2001-08-14 BR BR0113235-0A patent/BR0113235A/pt not_active Application Discontinuation
- 2001-08-14 MX MXPA03001389A patent/MXPA03001389A/es unknown
- 2001-08-14 WO PCT/US2001/041733 patent/WO2002014503A2/en not_active Application Discontinuation
- 2001-08-14 EP EP01975714A patent/EP1366153A2/en not_active Withdrawn
- 2001-08-14 PL PL01365789A patent/PL365789A1/xx not_active Application Discontinuation
- 2001-08-14 JP JP2002519631A patent/JP2004522412A/ja active Pending
- 2001-08-14 IL IL15441501A patent/IL154415A0/xx unknown
-
2003
- 2003-02-14 NO NO20030714A patent/NO20030714L/no unknown
Also Published As
Publication number | Publication date |
---|---|
KR20030048009A (ko) | 2003-06-18 |
WO2002014503A2 (en) | 2002-02-21 |
CN1537164A (zh) | 2004-10-13 |
US20020193329A1 (en) | 2002-12-19 |
AU2001295008A1 (en) | 2002-02-25 |
BR0113235A (pt) | 2004-06-08 |
CA2419533A1 (en) | 2002-02-21 |
WO2002014503A3 (en) | 2003-09-18 |
NO20030714L (no) | 2003-04-11 |
PL365789A1 (en) | 2005-01-10 |
EP1366153A2 (en) | 2003-12-03 |
JP2004522412A (ja) | 2004-07-29 |
MXPA03001389A (es) | 2004-05-04 |
IL154415A0 (en) | 2003-09-17 |
HUP0600780A2 (en) | 2007-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20030714L (no) | Blandinger og fremgangsmåter for behandling og diagnose av HER-2/NEU-assosierte maligniteter | |
NO20023402D0 (no) | Blandinger og fremgangsmåter for behandling og diagnose av prostatakreft | |
NO20013002L (no) | Blandinger og fremgangsmåter for behandling og diagnose av ovariekreft | |
NO20016427D0 (no) | Blandinger og fremgangsmåter for behandling av diagnose av lungekreft | |
NO20024972D0 (no) | Blandinger og fremgangsmåter for terapi og diagnose av brystkreft | |
NO20014769D0 (no) | Preparat for behandling og diagnose av bryst cancer og fremgangsmåter for anvendelse derav | |
NO983183L (no) | Blandinger og fremgangsmåte for behandling og diagnose av brystkreft | |
NO20022592L (no) | Forbindelser og fremgangsmåter for behandling og diagnose av Chlamydia-infeksjoner | |
NO20003853D0 (no) | Forbindelser for terapi og diagnose av lungekreft og metoder for deres anvendelse | |
NO20014223D0 (no) | Fremgangsmåte for diagnostisering og overvåkning av maligne brystkarsinoma | |
NO20010196D0 (no) | Sammensetninger og fremgangsmåter for terapi og diagnose av prostatakreft | |
DE59913141D1 (de) | Blutbehandlungsgerät | |
NO995690D0 (no) | Forbindelser for diagnose av tuberkulose og metoder for deres anvendelse | |
NO994932D0 (no) | Blandinger og fremgangsmaater for behandling og diagnose av brystkreft | |
NO20043246L (no) | Nye fremgangsmater til diagnose og behandling av tumorer | |
NO20015542D0 (no) | Fremgangsmåte for fremstilling og anvendelse av N- desmetylzopikloner | |
NO20024775D0 (no) | Hydroksyfenyl-piperidin-4-yliden-metyl-benzamidderivater til behandling av smerte | |
ZA200301204B (en) | Compositions and methods for the diagnosis and treatment of tumor | |
AU8678501A (en) | Compositions and methods for the diagnosis and treatment of tumor | |
DE60120291D1 (de) | Endoskop und Endoskopkapsel | |
NO20025594D0 (no) | Blandinger og fremgangsmåter for terapi og diagnose av brystkreft | |
NO20024776L (no) | Hydroksyfenyl-piperazinyl-metyl-benzamid derivater til behandling av smerte | |
NO20024777D0 (no) | Kinolinyl-piperidin-4-yliden-metyl-benzamidderivater til behandling av smerte | |
NO20014805L (no) | Blandinger og fremgangsmater for behandling og diagnose av brystkreft | |
NO20012612L (no) | Isonipecotamider for behandlingen av integrin-formidlede sykdommer |